Singapore, Nov. 8 -- Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) solutions for clinical trials, has announced the opening of a subsidiary in Japan, the world's third largest pharmaceutical market, where clinical developments have been expanding.

Based in Tokyo, the subsidiary will enable Kayentis to meet the logistical requirements of multi-national studies taking place in Asia-Pacific and cater to the needs of local CROs (Clinical Research Organizations) for digital data collection services with custom geographic capabilities.

Kayentis, which specializes in eCOA solutions for phases IIB/III, has been collaborating with local CRO partners in Japan since 2017. As many as 75 per cent of the clinical trial ...